MSCs: Clinical applications and European regulatory aspects

Mesenchymal Stromal Cells: Biology and Clinical Applications

Volumn , Issue , 2013, Pages 355-364

  Reinhardt, Jens ^a   Flory, Egbert ^a   Büttel, Isabel ^a   Schröder, Christa ^b   Fricke, Stefan ^c   Vucinic, Vladan ^c   Cross, Michael ^c   Niederwieser, Dietger ^c  

^a PAUL EHRLICH INSTITUT   (Germany)

^b ALBSTADT SIGMARINGEN UNIVERSITY   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84928162687     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-5711-4_18     Document Type: Chapter

References (23)

1. Prockop DJ (1997) Marrow stromal cells as stem cells for non-hematopoietic tissues. Science 276:71-74
2. Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, Benhaim P, Lorenz HP, Hedrick MH, (2001) Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng 7:211-228
3. In 't Anker PS, Scherjon SA, Kleijburg-van der Keur C, de Groot-Swings GM, Claas FH, Fibbe WE, Kanhai HH (2004) Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta. Stem Cells 22:1338-1345
4. In 't Anker PS, Noort WA, Scherjon SA, Noort WA, Scherjon SA, Kleijburg-van der Keur Keur C, Kruisselbrink AB, van Bezooijen RL, Beekhuizen W, Willemze R, Kanhai HH, Fibbe WE, (2003) Mesenchymal stem cells in human second-trimester bone marrow, liver, lung, and spleen exhibit a similar immunophenotype but a heterogeneous multilineage differentiation potential. Haematologica 88:845-852
5. Bieback K, Kern S, Kluter H, Eichler H (2004) Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. Stem Cells 22:625-634
6. Schallmoser K, Etchardt N, Strunk D, Rohde E (2012) Animal protein-free expansion of human mesenchymal stem/progenitor cells. In: Allan DS, Strunk D (eds) Regenerative medicine using blood-derived stem cells. Springer New York Dordrecht Heidelberg London pp 53-69
7. (2007) Regulation (EC) 1394/2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation No 726/2004 http://europa.eu/legislation_summaries/ internal_market/single_market_for_goods/pharmaceutical_and_cosmetic_products/ l21212_en.htm
8. Sensebe L, Bourin P, Tarte K (2011) Good manufacturing practices production of mesenchymal stem/stromal cells. Hum Gene Ther 22:1-8
9. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8:315-317
10. Buhring HJ, Battula VL, Treml S, Schewe B, Kanz L, Vogel W (2007) Novel markers for the prospective isolation of human MSC. Ann N Y Acad Sci 1106:262-271
11. Gang EJ, Bosnakovski D, Figueiredo CA, Visser JW, Perlingeiro RC (2007) SSEA-4 identifies mesenchymal stem cells from bone marrow. Blood 109:1743-1751
12. Quirici N, Soligo D, Bossolasco P, Servida F, Lumini C, Deliliers GL (2002) Isolation of bone marrow mesenchymal stem cells by anti-nerve growth factor receptor antibodies. Exp Hematol 30:783-791
13. Battula VL, Treml S, Bareiss PM, Gieseke F, Roelofs H, de Zwart P, Muller I, Schewe B, Skutella T, Fibbe WE, Kanz L, Buhring HJ, (2009) Isolation of functionally distinct mesenchymal stem cell subsets using antibodies against CD56, CD271, and mesenchymal stem cell antigen-1. Haematologica 94:173-184
14. Gentry T, Foster S, Winstead L, Deibert E, Fiordalisi M, Balber A (2007) Simultaneous isolation of human BM hematopoietic, endothelial and mesenchymal progenitor cells by flow sorting based on aldehyde dehydrogenase activity: implications for cell therapy. Cytotherapy 9:259-274
15. Yoon YS, Park JS, Tkebuchava T, Luedeman C, Losordo DW (2004) Unexpected severe calcification after transplantation of bone marrow cells in acute myocardial infarction. Circulation 109:3154-3157
16. Montag T, Nicol SB, Schurig U, Heiden M, Huber H, Sanzenbacher R, Flory E, Schwanig M, Schneider CK (2008) Microbial safety of cell based medicinal products-what can we learn from cellular blood components? Clin Chem Lab Med 46:963-965
17. Reinhardt J, Stuhler A, Blumel J, Reinhardt J, Stuhler A, Blumel J (2011) Safety of bovine sera for production of mesenchymal stem cells for therapeutic use. Hum Gene Ther 22:775; author reply 776
18. (1999) ICH harmonised tripartite guideline: specifications: test procedures and acceptance criteria for biotechnological/biological products - Q6B http://www.ema.europa.eu/docs/en_ GB/document_library/Scientific_guideline/2009/09/WC500002824.pdf
19. (CHMP), C. F. M. P. F. H. U. (2008) Guideline on human cell-based medicinal products http:// www.pei.de/nn_1743502/SharedDocs/Downloads/pu/innovationsbuero/guideline-on-human- cell-based-medicinal-products,templateId=raw,property=publicationFile.pdf/guideline-on- human-cell-based-medicinal-products.pdf
20. Devine SM, Cobbs C, Jennings M, Bartholomew A, Hoffman R (2003) Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood 101:2999-3001
21. Gao J, Dennis JE, Muzic RF, Lundberg M, Caplan AI (2001) The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs 169:12-20
22. Veldman T, Vignon C, Schrock E, Rowley JD, Ried T (1997) Hidden chromosome abnormalities in haematological malignancies detected by multicolour spectral karyotyping. Nat Genet 15:406-410
23. Pinkel D, Albertson DG (2005) Array comparative genomic hybridization and its applications in cancer. Nat Genet 37 Suppl:S11-17